AMGEN INC. $750,000,000 2.30% SENIOR NOTES DUE 2016 $1,000,000,000 4.10% SENIOR NOTES DUE 2021 $1,250,000,000 5.65% SENIOR NOTES DUE 2042 Underwriting AgreementAmgen Inc • June 30th, 2011 • Biological products, (no disgnostic substances) • New York
Amgen Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of $750,000,000 principal amount of the 2.30% Senior Notes due 2016 of the Company (the “2016 Notes”), an aggregate of $1,000,000,000 principal amount of the 4.10% Senior Notes due 2021 of the Company (the “2021 Notes”) and an aggregate of $1,250,000,000 principal amount of the 5.65% Senior Notes due 2042 of the Company (the “2042 Notes”, together with the 2016 Notes and the 2021 Notes, collectively, the “Securities”) to be issued pursuant to the provisions of an Indenture, dated as of August 4, 2003 (the “Indenture”), between the Company and the Bank of New York Mellon, as successor to JPMorgan Chase Bank, N.A., as Trustee (the “Trustee”).
